SCHEMBL6165216

SCHEMBL6165216

CC(CC(=O)O)c1ccc(NC(=O)Cc2ccc3nc(Nc4ccccc4)oc3c2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IL6 P05231 1/20 0.42
STAT3 P40763 1/20 0.42
CSNK1D P48730 1/20 0.41
ITGB1 P05556 4/20 0.40
ITGA4 P13612 4/20 0.40
HSD17B10 Q99714 1/20 0.40
HDAC6 Q9UBN7 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
P2RY14 Q15391 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPC1 O15118 3/20 0.38
PKM P14618 2/20 0.38
LMNA P02545 1/20 0.38
KDR P35968 1/20 0.38
ALDH1A1 P00352 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6165223 1.00 IL6 (0.42) IL6STAT3CSNK1DITGB1ITGA4
SCHEMBL6165048 0.93 ALDH1A1 (0.41) IL6STAT3CSNK1DITGB1ITGA4
SCHEMBL6162294 0.91 KMT2A (0.45) HSD17B10HDAC6P2RY14MEN1KMT2A
SCHEMBL6165644 0.91 HSD17B10 (0.39) IL6STAT3CSNK1DITGB1ITGA4
SCHEMBL6163082 0.91 ITGA4 (0.47) CSNK1DITGB1ITGA4NPC1PKM
SCHEMBL6166106 0.90 CSNK1D (0.42) CSNK1DITGB1ITGA4HDAC6HDAC3
SCHEMBL6161296 0.90 SOAT1 (0.40) IL6STAT3CSNK1DITGB1ITGA4
SCHEMBL6164611 0.90 CSNK1D (0.42) CSNK1DITGB1ITGA4HDAC6HDAC3
SCHEMBL6165215 0.90 ITGA4 (0.43) CSNK1DITGB1ITGA4P2RY14
SCHEMBL6164584 0.90 ITGA4 (0.46) ITGB1ITGA4HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6706738-B2 ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS AVENTIS PHARMA LIMITED (GB) 2004-03-16 US claimed
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists AVENTIS PHARMA LIMITED (GB) 2002-11-21 US claimed
EP-1183254-B1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LTD (GB) 2005-01-12 EP disclosed
US-6706738-B2 ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS AVENTIS PHARMA LIMITED (GB) 2004-03-16 US disclosed
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists AVENTIS PHARMA LIMITED (GB) 2002-11-21 US disclosed
EP-1183254-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS Aventis Pharma Limited (GB) 2002-03-06 EP disclosed
WO-2000061580-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LIMITED (GB) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists VCAM1, ITGA4, ITGA1 IL6 2330/4885STAT3 1381/4885CSNK1D 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.